ECEIX Performance — Lazard Emerging Markets Core Equity Portfolio, Institutional Shares
Data updated: 2025-11-24
ECEIX returned +16.58% over one year to Sep 2025. Annualised returns are +18.97% over 3 years and +4.80% over 5 years. The fund beat its Emerging Markets Equity category average: $100 invested three years ago grew to $168, against $161 for the category, and to $117 over one year, against $116. Volatility over the past three years was 15.47% a year. In the 12 months to Sep 2025 the fund took in a net $1.5M, and assets reached $140.75M.
ECEIX Growth of $100
What $100 invested in Lazard Emerging Markets Core Equity Portfolio grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Emerging Markets Equity category average over the same months.
| Period | ECEIX | Category average |
|---|---|---|
| 1 year (Oct 2024 – Sep 2025) | $117 | $116 |
| 3 years (Oct 2022 – Sep 2025) | $168 | $161 |
| 5 years (Oct 2020 – Sep 2025) | $126 | $142 |
| Since data start (Jul 2019 – Sep 2025) | $127 | $151 |
ECEIX Trailing Returns
Total returns to Sep 2025, from SEC N-PORT.
| Period | Total return |
|---|---|
| 1 year | +16.58% |
| 3 years (annualised) | +18.97% |
| 5 years (annualised) | +4.80% |
ECEIX Annual Returns
Calendar-year total returns of Lazard Emerging Markets Core Equity Portfolio, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2025 (Jan–Sep) | +25.52% |
| 2024 | +7.24% |
| 2023 | +12.30% |
| 2022 | −21.63% |
| 2021 | −11.20% |
| 2020 | +11.97% |
| 2019 (Jul–Dec) | +8.24% |
ECEIX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | +2.0% | −0.1% | +0.8% | +0.9% | +4.7% | +5.7% | +1.6% | +1.5% | +6.1% | — | — | — |
| 2024 | −3.5% | +4.7% | +2.7% | −0.2% | +1.8% | +3.4% | −0.6% | +1.1% | +5.4% | −4.7% | −2.1% | −0.4% |
| 2023 | +10.5% | −6.3% | +4.2% | −1.2% | −1.7% | +4.3% | +5.2% | −6.9% | −2.9% | −2.5% | +6.9% | +3.8% |
| 2022 | −1.0% | −6.6% | −2.4% | −6.8% | +1.2% | −7.9% | +2.1% | −0.6% | −11.5% | +0.7% | +14.6% | −3.5% |
| 2021 | +2.5% | +1.6% | −2.2% | +0.6% | +1.2% | −0.2% | −6.6% | −0.1% | −5.0% | +1.6% | −5.4% | +0.7% |
| 2020 | −5.6% | −4.9% | −19.4% | +8.0% | +2.3% | +6.6% | +9.3% | +1.9% | −1.7% | +1.8% | +9.8% | +7.5% |
| 2019 | — | — | — | — | — | — | −1.4% | −4.9% | +2.9% | +3.6% | +0.4% | +7.8% |
ECEIX Risk
Risk measures from monthly returns over Oct 2022 – Sep 2025.
- 3-year volatility (annualised): 15.47%
- 3-year Sharpe ratio: 0.94 (vs 4.5% risk-free rate)
- Best month: +14.65% (Nov 2022)
- Worst month: −6.88% (Aug 2023)
ECEIX Fund Flows
Monthly money in and out of Lazard Emerging Markets Core Equity Portfolio, from SEC Form N-PORT.
- 12-month net flow: $1.5M
- 12-month gross sales (incl. reinvestments): $31.0M
- Sales ÷ redemptions: 1.05×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Sep 2025 | $1.7M | $3.2M | −$1.5M |
| Aug 2025 | $4.0M | $2.3M | $1.7M |
| Jul 2025 | $2.1M | $4.6M | −$2.6M |
| Jun 2025 | $1.3M | $1.8M | −$462K |
| May 2025 | $740K | $1.9M | −$1.1M |
| Apr 2025 | $1.5M | $1.7M | −$181K |
| Mar 2025 | $3.4M | $4.5M | −$1.1M |
| Feb 2025 | $1.3M | $1.6M | −$285K |
| Jan 2025 | $8.3M | $2.0M | $6.2M |
| Dec 2024 | $2.4M | $2.6M | −$168K |
| Nov 2024 | $1.4M | $1.4M | −$55K |
| Oct 2024 | $2.9M | $1.8M | $1.0M |
ECEIX Assets Under Management
Net assets of Lazard Emerging Markets Core Equity Portfolio by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2025-09-30 | $140.75M |
| 2025-06-30 | $132.39M |
| 2025-03-31 | $120.18M |
| 2024-12-31 | $112.21M |
| 2024-09-30 | $121.34M |
| 2024-06-30 | $116.29M |
| 2024-03-31 | $117.25M |
| 2023-12-31 | $118.52M |
| 2023-09-30 | $115.37M |
| 2023-06-30 | $139.28M |
| 2023-03-31 | $99.58M |
| 2022-12-31 | $90.53M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.